Shanghai 4 antibody drugs passed acceptance

Shanghai independent research and development,known as "bio-missile" of the,Jianrufu,Isep,Kenni, 4 antibody drugs, recently through the Shanghai Science and Technology Commission organized by experts acceptanceAntibody drugs are protein molecules that mimic the autoimmune response of the human body and use modern bioengineering techniques to combat various types ofdiseasesin vitroThere is a unique correspondence between them and pathogen molecules, that is, an antibody recognizes only one pathogen, so it is called a true target drug, with a killer,apoptosis, blocking binding with other proteins characteristic,and low side effects, high efficacy The four antibody drugs approved were targeted at breast cancer, psoriasis (
psoriasis), rheumatoid arthritis, and anti-transplant rejection According to the introduction , the of pyrethroids for breast cancer patients more effective than similar imported products 1 times , can greatly reduce the dose of chemotherapy drugs The recurrence rate of psoriasis can be reduced to a very low , without harming any beneficial immune cells Isep not only quickly relieves joint swelling and pain , but also can effectively prevent joint deformation Kinnithin can inhibit the self-attack of immune cells and avoid the acute rejection after organ transplantation At present, Isep has been listed, epting and kiniquine have completed clinical trials, will soon declare a new drug certificate, Kenjofu has been clinical approval Reports show that Shanghai is in the leading domestic level in antibody drug development, in the State Drug Administration approved 11 antibody-type domestic new drugs, 10 from Shanghai It is reported that the world has so far been approved for the market of antibody drugs only 17 (
reprinted from Health Daily)